Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.